Go to Page # Page of 47

New Developments in Myeloma and Lymphoma

 Steve Schey
Description: Study includes Diagnostics and Prognostics: Individualizing Treatment, Novel agents: New drugs, drug combinations, drug scheduling, and the role in stem cell transplantation, Immunomodulation and antibodies, resistance. Other topics discussed include individualizing treatment in the ERA, gene expression and profiling and increasing options for newly diagnosed. Potential biological targets for novel anti-myeloma drugs, and new agents in myeloma.
Views: 3408
Domain: Medical
Category: Biology
Latest developments in haematological oncology g gy
Steve Schey
Consultant Haematologist King's College Hospital NHS Foundation Trust Kings College, London g g

New developments in Myeloma and p y Lymphoma
Diagnostics and Prognostics: Diagnostics and Prognostics:
Individualising Treatment

Novel Agents: N lA t
New drugs Drug Combinations Drug Scheduling Role in Stem cell transplantation

Immunom ... See more

Recent Presentations

Impact of Clinician Burnout on Patient Safety

Main objective is to identify strategies for improving well-being & resilience in the healthcare workforce. Explain, clinician burnout is a patient care & healthcare workforce prob

Paul Abramowitz
27 June, 2019

Innovation in Allergy Immunotherapy

ASIT biotech treatments consist of a mixture of purified peptides from different selected sizes, produced from natural sources of allergens for allergy immunotherapy.

26 June, 2019
Bionure Farma
25 June, 2019